Payment overview · 2025
General Payments
$562.02
24 reported records · 11 companies
Healthcare provider profile · identity verified
Aaron Taylor Clark, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · STATESBORO, GA · NPI 1134439581
Verified facts
What the public records show
CMS Open Payments records show Aaron Taylor Clark, M.D. received $562.02 in general payments during 2025 across 24 reported records.
Abbott Laboratories accounted for 46.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Symbicort by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $260.85 | 46.4% | 7 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $73.31 | 13.0% | 4 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $49.28 | 8.8% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $36.72 | 6.5% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $32.58 | 5.8% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $23.15 | 4.1% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $20.59 | 3.7% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $17.60 | 3.1% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $16.45 | 2.9% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $16.18 | 2.9% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.31 | 2.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $562.02 | 24 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AVEIR Normalized: aveir |
Device | Abbott Laboratories | $125.86 | 5 | 2025 |
Source payment records
|
|||||
| GALLANT Normalized: gallant |
Device | Abbott Laboratories | $98.81 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $73.31 | 4 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $49.28 | 3 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $36.72 | 2 | 2025 |
Source payment records
|
|||||
| JOT DX Normalized: jot dx |
Device | Abbott Laboratories | $36.18 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $23.15 | 1 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $20.59 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $17.60 | 1 | 2025 |
Source payment records
|
|||||
| RELISTOR Normalized: relistor |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $16.98 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $16.45 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $16.18 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $15.60 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $15.31 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
73 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 769 | 155 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 697 | 72 |
| Amlodipine Besylate | Amlodipine Besylate | 513 | 106 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 465 | 70 |
| Prednisone | Prednisone | 392 | 219 |
| Lisinopril | Lisinopril | 337 | 71 |
| Carvedilol | Carvedilol | 335 | 76 |
| Metformin Hcl | Metformin Hcl | 306 | 59 |
| Hydrochlorothiazide | Hydrochlorothiazide | 300 | 68 |
| Gabapentin | Gabapentin | 298 | 57 |
| Levothyroxine Sodium | Levothyroxine Sodium | 274 | 55 |
| Furosemide | Furosemide | 270 | 60 |
| Montelukast Sodium | Montelukast Sodium | 263 | 49 |
| Azithromycin | Azithromycin | 247 | 160 |
| Losartan Potassium | Losartan Potassium | 209 | 47 |
| Carisoprodol | Carisoprodol | 203 | 29 |
| Omeprazole | Omeprazole | 197 | 43 |
| Clonazepam | Clonazepam | 196 | 39 |
| Zolpidem Tartrate | Zolpidem Tartrate | 164 | 29 |
| Pantoprazole Sodium | Pantoprazole Sodium | 157 | 37 |
| Pioglitazone Hcl | Pioglitazone Hcl | 149 | 23 |
| Tamsulosin Hcl | Tamsulosin Hcl | 144 | 28 |
| Simvastatin | Simvastatin | 142 | 30 |
| Januvia | Sitagliptin Phosphate | 139 | 22 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 135 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 128 | 40 |
| Oxycodone Hcl | Oxycodone Hcl | 128 | 20 |
| Famotidine | Famotidine | 126 | 33 |
| Jardiance | Empagliflozin | 125 | 17 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 125 | 17 |
| Allopurinol | Allopurinol | 121 | 22 |
| Potassium Chloride | Potassium Chloride | 117 | 28 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 116 | 27 |
| Celecoxib | Celecoxib | 115 | 25 |
| Metoprolol Succinate | Metoprolol Succinate | 113 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 112 | 23 |
| Mounjaro | Tirzepatide | 110 | 19 |
| Pregabalin | Pregabalin | 105 | 17 |
| Tramadol Hcl | Tramadol Hcl | 105 | 22 |
| Doxazosin Mesylate | Doxazosin Mesylate | 103 | 20 |
| Tizanidine Hcl | Tizanidine Hcl | 103 | 22 |
| Diclofenac Sodium | Diclofenac Sodium | 96 | 31 |
| Rybelsus | Semaglutide | 96 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 93 | 24 |
| Amitriptyline Hcl | Amitriptyline Hcl | 89 | 18 |
| Ondansetron Odt | Ondansetron | 89 | 28 |
| Fenofibrate | Fenofibrate Nanocrystallized | 88 | 21 |
| Eliquis | Apixaban | 85 | 15 |
| Vascepa | Icosapent Ethyl | 85 | 19 |
| Glipizide | Glipizide | 80 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 77 | 15 |
| Warfarin Sodium | Warfarin Sodium | 74 | suppressed |
| Alprazolam | Alprazolam | 73 | 12 |
| Farxiga | Dapagliflozin Propanediol | 73 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 72 | 12 |
| Meloxicam | Meloxicam | 69 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 66 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 65 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 65 | 12 |
| Finasteride | Finasteride | 62 | 11 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 59 | 16 |
| Atenolol | Atenolol | 57 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 53 | 45 |
| Trazodone Hcl | Trazodone Hcl | 52 | 12 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 50 | suppressed |
| Linzess | Linaclotide | 50 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 50 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 50 | 14 |
| Ozempic | Semaglutide | 49 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 47 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 44 | 11 |
| Clonidine Hcl | Clonidine Hcl | 42 | suppressed |
| Bupropion Xl | Bupropion Hcl | 40 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 40 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 40 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 39 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 39 | suppressed |
| Myrbetriq | Mirabegron | 37 | suppressed |
| Xarelto | Rivaroxaban | 37 | suppressed |
| Spironolactone | Spironolactone | 36 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 35 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 35 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 34 | suppressed |
| Levemir Flexpen | Insulin Detemir | 33 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 32 | suppressed |
| Cephalexin | Cephalexin | 32 | 23 |
| Ibuprofen | Ibuprofen | 32 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 32 | suppressed |
| Diazepam | Diazepam | 31 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 30 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 30 | suppressed |
| Temazepam | Temazepam | 30 | suppressed |
| Baclofen | Baclofen | 29 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 29 | suppressed |
| Dexamethasone | Dexamethasone | 28 | 20 |
| Entresto | Sacubitril/Valsartan | 28 | suppressed |
| Topiramate | Topiramate | 28 | suppressed |
| Trulicity | Dulaglutide | 28 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 27 | suppressed |
| Synthroid | Levothyroxine Sodium | 27 | suppressed |
| Methocarbamol | Methocarbamol | 26 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 26 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 26 | suppressed |
| Ezetimibe | Ezetimibe | 25 | suppressed |
| Naproxen | Naproxen | 25 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 24 | suppressed |
| Lansoprazole | Lansoprazole | 24 | suppressed |
| Lorazepam | Lorazepam | 24 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 24 | suppressed |
| Amoxicillin | Amoxicillin | 23 | 19 |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 23 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 23 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 23 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Fluconazole | Fluconazole | 21 | 12 |
| Glimepiride | Glimepiride | 21 | suppressed |
| Irbesartan | Irbesartan | 21 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 21 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 20 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 20 | suppressed |
| Ketoconazole | Ketoconazole | 19 | suppressed |
| Novolog Flexpen | Insulin Aspart | 19 | suppressed |
| Tradjenta | Linagliptin | 19 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | suppressed |
| Mupirocin | Mupirocin Calcium | 18 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 18 | suppressed |
| Levetiracetam | Levetiracetam | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | 13 |
| Colchicine | Colchicine | 16 | suppressed |
| Lactulose | Lactulose | 16 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 16 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 16 | suppressed |
| Digoxin | Digoxin | 15 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 15 | suppressed |
| Glipizide Er | Glipizide | 15 | suppressed |
| Lovastatin | Lovastatin | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 14 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 14 | suppressed |
| Invokana | Canagliflozin | 14 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 13 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | 12 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Probenecid-Colchicine | Probenecid/Colchicine | 12 | suppressed |
| Roflumilast | Roflumilast | 12 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 12 | suppressed |
| Xtampza Er | Oxycodone Myristate | 12 | suppressed |
| Efavirenz-Emtric-Tenofov Disop | Efavirenz/Emtricit/Tenofovr Df | 11 | suppressed |
| Haloperidol | Haloperidol | 11 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $562.02 · 24 records | Abbott Laboratories | AIRSUPRA, AUSTEDO XR, AVEIR, Auvelity, CAPLYTA, Dexcom G6 Transmitter, FANAPT, GALLANT, JOT DX, Kerendia, RELISTOR, The Cologuard Plus Collection Kit, VERQUVO, XIFAXAN | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error